Remove Heart Failure Remove Heart Transplant Remove Outcomes
article thumbnail

RELIEVE-HF: Interatrial shunt in patients with heart failure

Cardiology Update

RELIEVE-HF investigators evaluated the efficacy and safety of the V-wave interatrial shunt system in patients with heart failure. The primary endpoint was a composite of all-cause mortality, left ventricular assist device (LVAD)/heart transplantation, HF hospitalizations, worsening HF, and KCCQ score changes. Atlanta, GA.

article thumbnail

Resynchronization-defibrillation for heart failure shows long-term benefits

Cardiology Update

The Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT; NCT00251251 ) demonstrated a greater 5-year mortality benefit for patients receiving cardiac-resynchronization therapy (CRT) compared to those receiving implantable cardioverter–defibrillators (ICDs). Secondary outcomes were experienced by 77.7%

article thumbnail

Endotronix Receives FDA Premarket Approval of the Cordella PA Sensor System for the Treatment of Heart Failure

DAIC

a privately held company dedicated to advancing the treatment of heart failure ( HF ) at the intersection of digital health and medtech, today announced Premarket Approval (PMA) from the U.S milla1cf Mon, 06/24/2024 - 20:21 June 24, 2024 — Endotronix, Inc. ,

article thumbnail

Case report of belt electrode-skeletal muscle electrical stimulation for acute heart failure with severe obesity: a novel therapeutic option for acute phase rehabilitation

Frontiers in Cardiovascular Medicine

Background Belt electrode skeletal muscle electrical stimulation (B-SES) is an emerging therapy anticipated to yield more favorable outcomes than conventional neuromuscular electrical stimulation (NMES), owing to its larger stimulation area. However, information on its efficacy and safety in patients with heart failure remains limited.

article thumbnail

Right Ventricular Function on Cardiovascular Magnetic Resonance Imaging and Long-Term Outcomes in Stable Heart Transplant Recipients

Circulation: Cardiovascular Imaging

BACKGROUND:In heart transplant recipients, right ventricular (RV) dysfunction may occur for a variety of reasons. Whether RV dysfunction in the stable phase after heart transplantation is associated with long-term adverse outcomes is unknown. years after heart transplantation were included.

article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,

CMS 111
article thumbnail

Impact of Advanced Therapy Centers on Characteristics and Outcomes of Heart Failure Admissions

Circulation: Heart Failure

Circulation: Heart Failure, Ahead of Print. Centers performing at least 1 heart transplant or left ventricular assist device were classified as ATCs. Patient characteristics, outcomes, and procedural volume were compared among 3 cohorts: admissions to non-ATCs, admissions to ATCs, and transfers to ATCs.